📣 𝗧𝗵𝗲 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗕𝗮𝗿𝗼𝗺𝗲𝘁𝗲𝗿 𝘀𝘂𝗿𝘃𝗲𝘆 𝗶𝘀 𝗻𝗼𝘄 𝗼𝗽𝗲𝗻! In just 10 minutes, you can help create a valuable data-driven snapshot of the Swedish life science industry. 💡 𝗪𝗵𝗼 𝘀𝗵𝗼𝘂𝗹𝗱 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝘁𝗲? Senior management from companies and organizations within the life science sector, as well as those supporting the industry, such as service providers and investors. 💡 𝗪𝗵𝘆 𝗶𝘀 𝘆𝗼𝘂𝗿 𝗶𝗻𝗽𝘂𝘁 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁? Your participation helps promote and strengthen the Swedish life science industry by providing critical data for informed decisions and international benchmarking. Last year, 200 companies took part in the survey. We hope more will join this year in this unique effort to gather essential insights and help our industry thrive 🪴📈 🔗 For more information: https://lnkd.in/dAgF7DY5 🔗 Direct link to survey: https://lnkd.in/dKi8Pc6T Produced by SwedenBIO in partnership with Medicon Village, Sahlgrenska Science Park, Stockholm Science City, Citeline and STUNS Life science
STUNS Life science
Samhällsorganisationer och sociala organisationer
STUNS Life science promotes the growth of a strong and sustainable life science sector.
Om oss
STUNS Life science supports growth and international competitiveness in life science. STUNS Life science is an independent and not-for-profit actor and a significant driving force for many developments within the region. The organization ensures a holistic perspective and offers a neutral meeting place. Continued collaboration – regional, national, and international – is vital for the sector to continue to develop and grow. We bring together relevant expertise and resources from the universities, companies, healthcare, and society to support a wide variety of collaborations, projects, and events.
- Webbplats
-
http://www.stuns.se
Extern länk för STUNS Life science
- Bransch
- Samhällsorganisationer och sociala organisationer
- Företagsstorlek
- 2–10 anställda
- Huvudkontor
- Uppsala
- Typ
- Ideell organisation
- Grundat
- 1983
- Specialistområden
- Innovation support, Networking, Health och Life science
Adresser
-
Primär
Uppsala Science Park
Uppsala, 75183, SE
Anställda på STUNS Life science
Uppdateringar
-
📍Reporting from Malmö at the Nordic Life Science Days! We're excited to be at NLSDays with the BRIDGE Sweden project, exploring collaborations to advance biological product development and strengthen Swedish life science. Meet Fanny Blom and Malin Wiederholm at booth C13 together with project partners Testa Center, Lund Stem Cell Center and pre-GMP Facility at Lunds universitet and SciLifeLab Drug Discovery & Development. #NLSDays
🌟 We’re live! Welcome to our new LinkedIn page! 🌟 We’re excited to officially launch our project page as we participate at the Nordic Life Science Days. It’s an honor to share our vision and plans at such an important event. Follow us here for the latest updates and insights from our project! What can you expect from our page? 📅 Invitations to seminars 🔬 Insights related to biological product development 📰 News and milestones from the project 🌍 Updates from conferences and events Visit us at booth C13 at Nordic Life Science Days where Jesper Hedberg, Alexandra Patriksson, Elias Uhlin, Niklas Berndt Thalén, Malin Wiederholm, and Fanny Blom are present, representing Testa Center, Lund Stem Cell Center & pre-GMP Facility at Lunds universitet, the SciLifeLab Drug Discovery & Development platform and STUNS Life science to learn more about BRIDGE Sweden.
-
How can small and growing companies in the life science sector work with sustainability?🌍 On September 24th, you have the chance to gain valuable insights at Stockholm Science City's breakfast seminar. You’ll meet Urban Adolfsson, CFO at Gradientech as well as STUNS very own Fanny Blom - who will share her top tips on how to implement sustainability in a way that suits your business. There are still spots available – Register now!
Varmt välkomna till vårt frukostseminarium 24 september: Hållbarhet för växande life science-företag. För företag inom life science står självklart ett av de 17 globala hållbarhetsmålen i fokus: att bidra till god hälsa och välbefinnande. Att ligga steget före även på andra områden inom hållbarhet kan ge affärsnytta och förbättra möjligheterna till finansiering och lyckade rekryteringar. Läs mer och anmäl ➡ dig https://lnkd.in/dxY_AXtm Talare är Fanny Blom på STUNS Life science och Urban Adolfsson på Gradientech. Moderator är Andreas Namslauer, Stockholm Science City. #lifescience #Hagastaden #hållbarhet #sustainability
Innehållet är inte tillgängligt här
Få tillgång till det här innehållet och mycket mer i LinkedIns app
-
Thank you to everyone who participated in yesterday’s kick-off and investment meeting at Bjerking! 🙌 Special thanks to the BIO-X winners – ArgusEye, Rarity Bioscience , Readily Diagnostics , Phenaros Pharmaceuticals , Strike Pharma AB – and the BIO-X runner ups – Cellda AB, Stardots, Extem Pharma, Oxlantic Medical – who truly impressed us with their pitches. We are excited to follow your journey in the BIO-X Accelerate program and look forward to the progress you’ll make in the Life-Science industry.🚀 We would also like to extend our gratitude to our partner Connect Sverige Region Uppsala for your support!
-
A new round of BIO-X Accelerate is now commencing. We are pleased to welcome five selected companies: ArgusEye, Phenaros Pharmaceuticals, Rarity Bioscience , Readily Diagnostics, and Strike Pharma AB. Last in line to presented is the company Readily Diagnostics. Readily Diagnostics' technology is based on padlock probes and rolling circle amplification (RCA), combined with a proprietary solution to enhance speed. It integrates a molecular method with microfluidics, allowing for use in various settings or with standard laboratory equipment for high throughput. This technology offers the robustness and specificity of RT-PCR without requiring specialized instruments. "We are incredibly excited and honored to have been selected for the BIO-X Accelerate program! We see this as validation that our diagnostic tests will make a significant difference in healthcare. With the support of BIO-X Accelerate, we can now take further steps to develop our clinical test, advance our regulatory journey towards CE-IVD certification, and offer it to healthcare providers more quickly." — Liza Löf (Mokvist), PhD, CEO. Are you an investor looking for new and exciting Life Science companies? Sign up for the BIO-X Accelerate Kickoff and Investment Meeting to meet Readily Diagnostics and nine other pitching companies. Register here: https://lnkd.in/diurc_gd Funding is available through European Regional Development Fund (ERDF) administered by The Swedish Agency for Economic and Regional Growth (Tillväxtverket).
-
A new round of BIO-X Accelerate is now commencing. We are pleased to welcome five selected companies: ArgusEye, Phenaros Pharmaceuticals, Rarity Bioscience , Readily Diagnostics, and Strike Pharma AB. Next in line is the company Phenaros Pharmaceuticals. Phenaros Pharmaceuticals use AI and automation to accelerate drug discovery. They employ state-of-the-art AI to guide decisions, along with robotics and automation for intelligent experimentation. As a data-centric company, Phenaros Pharmaceuticals systematically engineers the data used to build their AI system, enabling them to perform the right experiments at the right time, while reducing costs and time in drug discovery cycles. "BIO-X Accelerate offers substantial value for us by providing funding and strategic support to validate and scale our drug discovery platform. This initiative allows us to solidify our technology by partnering with leading pharmaceutical companies and enhances our ability to contribute to bringing effective drugs to market faster." — Jordi Carreras Puigvert, CSO. Are you an investor looking for new and exciting Life Science companies? Sign up for the BIO-X Accelerate Kickoff and Investment Meeting to meet Phenaros Pharmaceuticals and nine other pitching companies. Register here: https://lnkd.in/diurc_gd Funding is available through European Regional Development Fund (ERDF) administered by The Swedish Agency for Economic and Regional Growth (Tillväxtverket).
-
A new round of BIO-X Accelerate is now commencing. We are pleased to welcome five selected companies: ArgusEye, Phenaros Pharmaceuticals, Rarity Bioscience , Readily Diagnostics, and Strike Pharma AB. Next in line is the company Strike Pharma AB. Strike Pharma is using the company’s proprietary Adaptable Drug Affinity Conjugate (ADAC) technology to take precision medicine to a new level, enabling development of truly individualized immunotherapeutic treatments based on the genetic profile of each patient’s tumor. "BIO-X Accelerate not only accelerates our product validation contributing to the establishment of our unique technology now also positioned for antibody-based delivery of oligonucleotide-based therapeutics, but also establishes a foundation for future industrial partnerships. Being selected is a recognition of our project’s value to the industry, society, and patients.” Sara Mangsbo, CSO. Are you an investor looking for new and exciting Life Science companies? Sign up for the BIO-X Accelerate Kickoff and Investment Meeting to meet Strike Pharma and nine other pitching companies. Register here: https://lnkd.in/diurc_gd Funding is available through European Regional Development Fund (ERDF) administered by The Swedish Agency for Economic and Regional Growth (Tillväxtverket).
-
A new round of BIO-X Accelerate is now commencing. We are pleased to welcome five selected companies: ArgusEye, Phenaros Pharmaceuticals, Rarity Bioscience , Readily Diagnostics, and Strike Pharma AB. Next in line to be presented is the company ArgusEye. ArgusEye provides sensor solutions for real-time detection of biological systems and processes. The company’s patented sensor technology is the result of extensive academic research at Linköping University and is based on nanoplasmonic sensing combined with fiber optics. By adding specific receptors, the company can offer flexible and sensitive sensing systems for a variety of targets. "BIO-X Accelerate will help us accelerate towards our goal of developing biosensors that can fundamentally reshape the biopharmaceutical industry. This support allows us to prioritize product development of a new product which will further allow us to offer solutions that cover the entire bioprocessing chain." Nathalie Elsässer, COO ArgusEye. Are you an investor looking for new and exciting Life Science companies? Sign up for the BIO-X Accelerate Kickoff and Investment Meeting to meet ArgusEye and nine other pitching companies. Register here: https://lnkd.in/diurc_gd Funding is available through European Regional Development Fund (ERDF) administered by The Swedish Agency for Economic and Regional Growth (Tillväxtverket).
-
A new round of BIO-X Accelerate is now commencing. We are pleased to welcome five selected companies: ArgusEye, Phenaros Pharmaceuticals, Rarity Bioscience , Readily Diagnostics, and Strike Pharma AB. First to be presented is the company Rarity Bioscience . Rarity Bioscience was founded in 2021 as a spin-out from Uppsala University to further develop and commercialize the superRCA® assay technology. Rarity superRCA® is an ultrasensitive multiplex assay for detecting rare nucleic acid sequences in liquid biopsy or tissue samples. "BIO-X Accelerate gives us the opportunity to dedicatedly drive this project all the way to regulatory approval. It also validates our vision, ambition, and ability to impact and improve cancer care." - Linus Bosaeus, CEO Rarity Bioscience AB. Are you an investor looking for new and exciting Life Science companies? Sign up for the BIO-X Accelerate Kickoff and Investment Meeting to meet Rarity Bioscience and nine other pitching companies. Register here: https://lnkd.in/diurc_gd Funding is available through European Regional Development Fund (ERDF) administered by The Swedish Agency for Economic and Regional Growth (Tillväxtverket).
-
We thrilled to officially announce the pioneering companies selected for the BIO-X Accelerate program! Congratulations to: 🌟 ArgusEye – Revolutionizing bioprocessing with advanced biosensors. 🌟 Rarity Bioscience – Pioneering precision cancer diagnostics. 🌟 Readily Diagnostics – Developing rapid and impactful diagnostic tests. 🌟 Phenaros Pharmaceuticals – Innovative drug development. 🌟 Strike Pharma AB – Taking precision medicine to a new level. “We are very pleased to welcome these five innovative companies to the BIO-X Accelerate program. Previous rounds have shown that our support has contributed to companies attracting significant investment and taking important steps forward in their development. With the new participants, we look forward to continuing to drive innovation in life science and health, and contribute to a sustainable and digital transformation." – Dajana I., Project Manager for the BIO-X Accelerate program at STUNS. BIO-X Accelerate was initiated in 2020 with the goal of facilitating the transition of small and medium-sized enterprises within the region’s life science sector from the early stages to a rapid phase of innovation and growth. The project aimed to enhance the competitiveness of these companies by generating innovative products that have high demand in the global healthcare market. The BIO-X Accelerate program will be in progress during 2024-2026 with these companies and the new theme “IMPACT”. Read the full press release👇 https://lnkd.in/dFN99UQV This project is funded by The European Regional Development Fund (ERDF) via Tillväxtverket. Thanks to our strategic and supporting partners: UIC - Uppsala Innovation Centre, Connect Sverige Region Uppsala, LEAD (Business Incubator), Inkubera, Create Business Incubator, Linköpings universitet, Uppsala universitet and Örebro universitet Holding. #Uppsala #Lifescience #Innovation